Prestige’s PBP1510 Receives EMA’s Positive Opinion on Orphan Designation for Pancreatic Cancer

 Prestige’s PBP1510 Receives EMA’s Positive Opinion on Orphan Designation for Pancreatic Cancer

Prestige’s PBP1510 Receives EMA’s Positive Opinion on Orphan Designation for Pancreatic Cancer

Shots:

  • EMA’s COMP has granted a positive opinion for an ODD status to its PBP1510 for the treatment of pancreatic cancer. COMP’s positive will be sent to the EC which is expected to grant the orphan designation within 30 days
  • The ODD allows the Prestige to get exclusive rights to commercialize for 10yrs., following the regulatory approval in the future
  • PBP1510 is an anti-PAUF mAb for pancreatic cancer in P-I stages and has already received the US FDA’s and the Korean MFDS’ ODD status in Jun & July’2020 respectively

    Click here to­ read the full press release/ article | Ref: B3C Newswire | Image: Michael J Williams, DMD, PC

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post